ClinicalTrials.gg
RecruitingNCT07453537CRAN-MULTIUpdated Jun 30, 2026

Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy Adults

An interventional study of Cranberry juice and Placebo juice in Stress Response, Mental Stress and Multitasking Behavior and Multitasking Ability, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by University of Florida · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
30 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 290 studies in Stress, Psychological with a site in United States — 31 open to participants now, 46 under way, 1 of them phase 3. Stress, Psychological · United States.

Planned enrollment
130th of 262
84 · median 84
Started
2026
with 13 others
No phase
240 of 290
25 open now
Primary completion
2028-05
later than 36 of 45 live
Registered
280th of 290
by date

Among the 290 studies in Stress, Psychological with a site in United States, this one is the 130th largest by planned enrollment of the 262 interventional ones that give a count, is one of 14 that started in 2026, is one of 240 with no phase, reaches primary completion later than 36 of the 45 other live ones, and was the 280th registered.

Stress, Psychological

854 studies on the registry are indexed under Stress, Psychological; 141 are open to participants now.

Browse Stress, Psychological studies →

Open to participants now

31 of the 290 studies in Stress, Psychological with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Stress, Psychological studies recruiting now, 34 (46%) set no upper age limit and 36 (49%) stop at 75 or younger; 13 take children under 18; 49 take healthy volunteers.

This study: 30 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Stress, Psychological with a site in United States, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled clinical trial evaluates whether 70 days of daily cranberry juice consumption improves cognitive performance and motor accuracy and reduces psychological and physiological stress responses during a motor-cognitive dual-task multitasking challenge in healthy adults aged 30-55 (Aim 1). It is hypothesized that chronic cranberry juice intake will enhance dual-task performance and attenuate stress reactivity (Hypothesis 1). It is further hypothesized that cranberry juice will mitigate multitasking-related fatigue, mood fluctuations, and cognitive impairment, accompanied by favorable changes in circulating stress biomarkers and stress-regulatory neurochemical pathways (Aim 2/Hypothesis 2). Finally, the study incorporates gut analysis to determine whether cranberry juice induces beneficial shifts in the gut microbiota and microbial metabolites (e.g., SCFAs) and whether these changes are associated with improved cognitive and stress-related outcomes, consistent with a microbiome-gut-brain axis mechanism (Aim 3/Hypothesis 3).

Read the detailed description

Recruitment and Screening

Individuals who express interest will complete an initial study interest form. If preliminarily qualified, individuals will proceed to a screening process conducted via Qualtrics. Study staff will review responses to confirm eligibility and identify exclusions based on predefined criteria.

Study Design, Visits, and Timeline

This randomized, double-blind, placebo-controlled, parallel-design trial spans 13 weeks and includes three in-person visits: the consent visit (V1), the baseline visit (V2), and the final visit (V3).

Consent Visit (V1)

At V1, participants complete the informed consent process and undergo eligibility checks. These include measurement of height and weight to confirm BMI eligibility, pregnancy testing for female participants to ensure non-pregnant status, and a brief multitasking task capability check to confirm participants can comfortably perform the protocol tasks. Study staff will answer any questions, and V2 and V3 will be scheduled. Upon providing consent, participants enter the run-in phase.

Run-In Phase (Pre-Baseline)

Following V1, participants begin the run-in phase, adhering to the study's dietary restrictions. This includes avoiding cranberry products and specific polyphenol- or supplement-rich foods, as well as limiting caffeine and alcohol near visit days.

Baseline Visit (V2) and Final Visit (V3) Procedures

V2 (baseline) and V3 (final) follow the same structure, with the key difference being the assigned beverage at breakfast during V3.

Pre-Visit Requirements and Intake

Participants arrive after a 10-hour overnight fast. Upon arrival, participants submit a self-collected fecal sample for gut microbiome analysis. Compliance with dietary restrictions is confirmed, after which a phlebotomist draws a fasting blood sample (20 mL). Height and weight are measured.

Core Assessments (V2 and V3)

Multitasking (Dual-Task) Challenge and Stress Reactivity Participants perform a dual-task multitasking paradigm with continuous physiological monitoring. The cognitive task involves counting backward aloud from a random number between 800 and 999, subtracting by 3, 7, and 17 across three series. Each series lasts 4 minutes, with 90-second breaks in between, totaling 15 minutes. Scoring is based on the total correct/incorrect subtractions; if errors occur, participants continue from the new number. The motor task involves clicking rapidly shrinking dots on a screen, scored for target efficiency and accuracy. The multitasking session is video-recorded. Mood and stress are assessed using the State-Trait Anxiety Inventory (STAI-State) and Visual Analog Mood Scales (VAMS) immediately before and after the task. Saliva samples are collected immediately before, immediately after, and 60 minutes after the task to measure cortisol and alpha-amylase.

Standardized Meal (V2 vs. V3)

At V2, participants are served a standardized meal with water. At V3 (Day 70), the standardized meal remains the same, but water is replaced with 8 oz of the assigned beverage (either cranberry juice or placebo).

Cognitive Testing

Following the multitasking challenge and standardized meal, participants complete NIH Toolbox cognition and memory assessments.

Questionnaires and Symptom Monitoring

Participants complete measures assessing mental fatigue, perceived stress, and trait anxiety via Qualtrics.

Post-Visit and Follow-Up

After V2, participants leave with assigned beverages (8 oz per bottle; two bottles per day). V3, the final visit, mirrors V2, except the standardized meal includes 8 oz of the assigned beverage and an additional compliance questionnaire is administered. Participation ends after all final assessments are completed at V3.

03

Conditions studied

  • Stress Response
  • Mental Stress
  • Multitasking Behavior and Multitasking Ability
  • Physiological Stress
  • Cognitive Symptoms
  • Motor Activity
04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 110 pounds
  • Between 30 and 55 years
  • between 18.9 and 29.9 kg/m²
  • A minimum education level of high school or above

Exclusion criteria

Exclusion Criteria:

  • Heavy caffeine users (consuming more than 300 mg/day or more than two cups of coffee per day)
  • Alcohol consumption exceeding three drinks per week
  • A smoking history of 10 years or more, or current use of cannabis products
  • Uncontrolled hypertension
  • Clinically diagnosed illnesses such as diabetes, cardiovascular disease, neurological disorders, or mental health conditions
  • Participants currently taking prescribed anti-inflammatory medications, antibiotics, or antidepressants that may affect study outcomes, particularly those related to blood and fecal sample analysis
  • Individuals who regularly take vitamin or mineral supplements and are unwilling to discontinue them for the duration of the study will not qualify.
  • Participants must be willing to maintain their current daily routine and lifestyle, undergo body weight and height measurements, and notify study coordinators of any illnesses or significant adverse life events during the study period
  • Those with specific dietary restrictions that prevent them from consuming the standardized breakfast sandwich required in the study protocol
  • Participants must successfully complete the on-site multitasking task as a screening measure prior to signing consent.
  • Beck's Depression Inventory score of 21 or higher
  • Beck's Anxiety Inventory score of 21 or higher
  • A history of severe suicidal tendencies, or seasonal depression
  • Pregnancy and breastfeeding (Female participants must complete four pregnancy tests throughout the study and track their menstrual cycle. Those unwilling to comply with these requirements will not be eligible.)
  • Potential participants must not have taken any anti-inflammatory medications, antibiotics, or antidepressants within the past three months prior to the start of the study
  • Individuals who were previously enrolled in IRB#202300950 will be excluded due to the learning effect of cognitive tests, ensuring accurate data collection for this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Cranberry juice

    Cranberry juice will be provided by Ocean Spray Company.

    Other: Cranberry juice

  • Placebo comparator
    Placebo cranberry juice

    Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry beverage; it contains no active cranberry components.

    Other: Placebo juice

Interventions

  • OtherCranberry juice

    Participants will consume the cranberry juice beverage by mouth each day for 70 days following a run-in period.

  • OtherPlacebo juice

    Participants will consume the placebo cranberry juice beverage by mouth each day for 70 days following a run-in period.

06

What researchers measure

Primary outcomes

  1. Cognitive task performance (serial subtraction accuracy)

    Total number of correct subtractions during the multitasking cognitive task Measure Description: Counting backward aloud from a random number between 800-999 by 3, 7, and 17; performance scored as total correct subtractions across the task.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  2. Cognitive task performance (serial subtraction errors)

    Outcome Measure: Total number of incorrect subtractions during the multitasking cognitive task Measure Description: Same serial subtraction task; performance scored as total incorrect subtractions.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

Secondary outcomes

  1. Mood

    Change from baseline to end of intervention in mood assessed using the Visual Analog Mood Scale (VAMS). The VAMS is a self-report visual analog measure of current mood states collected during study visits per protocol.

    Time frame: Baseline (Visit 2; pre- and post-multitasking task) and Final (Visit 3, Day 70; pre- and post-multitasking task). Through study completion (average of 2 years).

  2. State anxiety

    Change from baseline to end of intervention in state anxiety assessed using the State-Trait Anxiety Inventory - State Subscale (STAI-State). The STAI-State is a self-report measure assessing state anxiety in response to multitasking stress collected during study visits per protocol.

    Time frame: Baseline (Visit 2; pre- and post-multitasking task) and Final (Visit 3, Day 70; pre- and post-multitasking task). Through study completion (average of 2 years).

  3. Mental fatigue

    Change from baseline to end of intervention in mental fatigue assessed using the Mental Fatigue Scale (MFS). The MFS is a self-reported questionnaire evaluating perceived mental fatigue and related cognitive symptoms. Scores will be collected during study visits and analyzed per protocol to assess changes following cranberry juice intervention.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  4. Sleep quality

    Change from baseline to end of intervention in sleep quality assessed using the Leeds Sleep Evaluation Questionnaire (LSEQ). The LSEQ is a self-report questionnaire evaluating subjective sleep quality and related dimensions of sleep and awakening, collected during study visits per protocol.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  5. Trait anxiety

    Change from baseline to end of intervention in trait anxiety assessed using the State-Trait Anxiety Inventory - Trait Subscale (STAI-Trait). The STAI-Trait is a self-report measure of trait anxiety.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  6. Food frequnecy questionnaire

    Dietary intake patterns assessed using a Food Frequency Questionnaire (FFQ). The FFQ is a self-report measure used to evaluate habitual dietary intake and food consumption frequency during the run-in phase and throughout the intervention period per protocol.

    Time frame: Run-in (pre-intervention), Baseline (Visit 2), Mid-Intervention, and Day 70 (Visit 3). Through study completion (average of 2 years).

  7. Picture vocabulary test

    NIH Toolbox Picture Vocabulary Test: to assess participants' ability to understand and identify the meaning of words by matching them to corresponding images.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  8. Flanker inhibitory control and attention test

    NIH Toolbox Flanker Inhibitory Control and Attention Test: to assess participants' cognitive control and attentional processes, specifically their ability to inhibit irrelevant information and focus on the relevant stimuli.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  9. List sorting working memory test

    NIH Toolbox List Sorting Working Memory Test: to assess participants' working memory abilities.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  10. Dimensional changes card sort test

    NIH Toolbox Dimensional Changes Card Sort Test: to assess the cognitive flexibility of participants.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  11. Pattern comparison processing speed test

    NIH Toolbox Pattern Comparison Processing Speed Test: to assess the cognitive processing speed of participants.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  12. Picture sequence memory test

    NIH Toolbox Picture Sequence Memory Test: to assess participants' episodic memory.

    Time frame: Time Frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  13. Auditory verbal learning test

    Auditory Verbal Learning Test: to assess participants' attention, memory, and learning ability in the auditory-verbal domain.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  14. Picture sequence memory test

    NIH Toolbox Picture Sequence Memory Test: to assess participants' episodic memory.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  15. Heart rate

    Heart rate (bpm) will be measured during multitasking.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  16. Interbeat interval (IBI)

    Interbeat interval (ms) will be measured during multitasking.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  17. Galvanic skin response (GSR)

    Galvanic skin response (μS) will be measured during multitasking.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  18. Salivary alpha-amylase activity

    Salivary alpha-amylase activity will be assessed using ELISA kit.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  19. Salivary cortisol level

    Salivary cortisol level will be measured by an enzyme immunoassay with the Cortisol Elisa Assay Kit.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

Other outcomes

  1. Gut microbiome composition and diversity

    Change from baseline to end of intervention in gut microbiome composition and diversity assessed from stool samples.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

  2. Short-chain fatty acids (SCFAs)

    Change from baseline to end of intervention in fecal concentrations of acetic acid, propionic acid, and butyric acid assessed from stool samples.

    Time frame: Baseline (Visit 2) and Final (Visit 3, Day 70). Through study completion (average of 2 years).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for May 2028, 21 months later.

Of 462 non-industry interventional studies with no phase under Stress, Psychological, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 21 months is above that.

Counting every sponsor, half of 475 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Mar 6, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
Aug 1, 2029
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07453537
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Jun 30, 2026

Study contacts

Maya E Waintraub, M.S.
Contact
mwaintraub@ufl.edu
847-246-2255
Lewei Gu, PhD
principal investigator · University of Florida

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion